Third ACT Canada Consortium Meeting
Hôtel Le Concorde Québec
1225 Cours du Général-de Montcalm
Quebec City, QC
Wednesday, October 9th – Thursday, October 10th, 2024

Presenters and Exhibitors
ACT Patient Engagement Committee Eva Friedman (Eva.Friedman@phri.ca) https://act-aec.ca/ The ACT Patient Engagement Committee (PEC) focuses on promoting effective patient involvement across the Consortium. Its primary role is to establish and support best practices for engaging patients in clinical trials and research initiatives. The committee acts as a resource for Consortium members by offering guidance, mentorship, and materials to help them partner with patients and integrate patient perspectives into their work. PEC also connects with networks and clinical trial units to understand how they currently involve patients the resources they use, aiming to identify opportunities for sharing and improvement. Additionally, the committee looks for potential gaps or challenges in patient engagement in clinical trials and works to address them by providing tools, conducting needs assessments, or creating new resources if necessary. Overall, the PEC's goal is to foster meaningful collaboration between patients and researchers, ensuring that patient voices are integrated throughout the research process.
APTEC Health Leyla Soleymaini (Leyla.soleymani@gmail.com) & Mahla Poudineh (mahla.poudineh@gmail.com) Continuous monitoring of clinically relevant biomarkers in interstitial fluid (ISF) has the potential to revolutionize healthcare, particularly for patients in critical care or for those being monitored at home. Aptec Health introduces Wearable Aptalyzer integrating pain-free, biocompatible microneedle arrays for ISF extraction with an electrochemical aptamer-based biosensor for realtime monitoring of blood analytes. Aptamers, unlike enzymatic sensors, enable the detection of a wide range of analytes, ranging from small molecules to proteins. This technology is especially promising for continuous monitoring of cardiac troponin (cTnI) in patients being treated or at risk of cardiovascular disease, as well as insulin monitoring for patients with diabetes using artificial pancreas devices.
Aufero Medical Daniel Gelman (dgelman@auferomedical.com) https://www.auferomedical.com/ Aufero Medical is a Canadian medical technology startup, focused on advancing cardiac ablation therapy. Our flagship product, TruContact, is an innovative accessory device designed to enhance catheter stability during ablation procedures, improving outcomes for atrial fibrillation (AF) patients. By providing on-demand stabilization for off-the-shelf commercial catheters, TruContact ensures consistent and efficient lesion formation, potentially decreasing AF recurrence and the need for costly repeat procedures. We collaborate with leading electrophysiologists, industry partners, and research institutions. Our mission is to establish strategic partnerships with healthcare providers and EP market leaders, ensuring the broad adoption of our technology and transforming the standard of care in cardiac ablation.

Presenters and Exhibitors
Bay Area Research Logistics *https://bayarearesearchlogistics.com/* Bay Area Research Logistics (BARL) specializes in providing comprehensive clinical trial supply chain services, including packaging, labeling, storage, and distribution. With a focus on precision and reliability, BARL ensures seamless logistics solutions for biopharma companies and researchers, maintaining compliance with cGMP standards and supporting clinical trials across North America. We are committed to delivering innovative and tailored services that optimize the success of clinical trials from start to finish.
BioTwin Manon Fradin (mfradin@biotwin.ai) & Pierre-Jérôme Légaré (PJLegare@biotwin.ai) https://www.biotwin.ai/ BioTwin is at the forefront of healthcare innovation, leveraging advanced biometrics from connected devices and non-invasive biological samples to create highly personalized human virtual twins. These virtual twins, projected by three patents, allow for precise modelling of individual health profiles based on thousands of biomarkers. By offering targeted profiles for diseases like breast cancer, diabetes, and Parkinson's disease, BioTwin's technology enhances clinical trial efficiency. Human virtual twins offer several key benefits to clinical trials, particularly in terms of reducing time, the number of participants, and overall costs (i.e., personalized modeling, continuous at-home monitoring, simulated trial runs, increased diversity, and reduced costs). Ultimately, BioTwin empowers clinical research with precise data-driven insights to improve treatment efficacy and patient outcomes.
Canurta Therapeutics Akeem Gardner (akeem@canurta.com) *https://www.canurta.com/* Canurta Therapeutics is pioneering the development of innovative therapies for neurodegenerative and inflammatory diseases. Our lead candidate, CNR-401, is a novel multi-target botanical drug formulated with a proprietary blend of flavonoids, cannabinoids, and terpenoids, offering a safer, more effective approach to ALS treatment. With a strong scientific foundation, CNR-401 targets key pathways such as neuroinflammation and neuroprotection, showing promise in preclinical models for improving motor function, reducing anxiety, and slowing disease progression. Our proprietary formulation ensures enhanced absorption and bioavailability. CNR-401 not only addresses unmet medical needs but also presents a pharmacoeconomic advantage by reducing treatment costs and improving patient outcomes. With a robust intellectual property portfolio and strategic partnerships, Canurta is poised to lead the next generation of botanical therapeutics.
Cardea Health Inc. Naveed Ahmad (Naveed.Ahmad@cardeahealth.io) www.Cardeahealth.io Cardea Health Inc. specializes in automating the pre-screening process for cardiometabolic clinical trials for outpatient clinics. Cardea uses proprietary LLM (Large Language Models),Optical Character Recognition (OCR) and Natural Language Processing (NLP) technologies. By streamlining patient identification, Cardea's platform significantly reduces manual work, increasing efficiency and data quality. Clinical trial sites benefit from seamless integration with existing workflows and a dramatic reduction in pre-screening time—from minutes to just seconds—ensuring that the right patients are matched to the most suitable trials quickly and accurately. Cardea Health's Cardiometabolic lexicon ensures unmatched precision in patient eligibility identification, far surpassing traditional methods. Our innovative solution not only accelerates trial recruitment but also cuts patient acquisition costs at the site level, making clinical trials more effective for research institutions across North America.

Presenters and Exhibitors
Care Access Andrew Hamilton (a.Hamilton@careaccess.com) & Dr. Berit Dool (Berit.Dool@careaccess.com) https://careaccess.com/ Care Access works around the world to make the future of health better for all. We help people learn more about their health, access health resources they need, and participate in research to help find new medicines and cures. With over 200 research sites across the globe, hundreds of traveling clinicians, and a fleet of over 150 mobile health clinics, we work with hundreds of communities each year to deliver care and research where it is most needed. Through our Future of Medicine program, we provide our members free health screenings, information about research studies, and other education and services. And through our Difference Makers program, we support and amplify the impact of local leaders and organizations that work to improve their communities' health and wellness.
CELLECT Laboratories Ibukun Elebute & Claire Murphy (cellectlaboratories@gmail.com) https://www.linkedin.com/company/cellectlaboratories/ CELLECT is pioneering the development of nanomaterial-embedded menstrual products that extract DNA from cervical and endothelial cells, as well as other analytes present in menstrual blood. This innovative technology allows for the diagnosis of critical reproductive health conditions, including HPV, early-stage cervical cancer, STDs, and endometriosis. CELLECT provides a non-invasive and comfortable alternative to traditional diagnostic methods, such as pap smears, enabling individuals to take control of their reproductive health from the comfort of their own homes. Designed to seamlessly integrate with existing gold-standard diagnostic techniques, CELLECT enhances accessibility, reducing the barriers to vital health screenings and providing an easier path to early detection and intervention.
Cura Therapeutics Inc. Claudia Penafuerte (claudiapd@curatherapeutics.com) https://www.curatherapeutics.com/ Cura Therapeutics is an IND-stage biotech company developing a first-in-class multifunctional immunotherapy platform to treat metastatic cancer, infectious diseases, and fibrotic diseases. Cura's approach harnesses the immune system's healing power. Cura's platform combines AI predictive protein modeling, experimental techniques, and deep domain pathway analysis expertise to create novel bio-engineered fusion proteins from immune system components. These immunotherapies activate and coordinate multiple immune system mechanisms, halting disease progression and restoring the body to a healthy state. Our lead immunotherapy, CT101, is the best/first-in-class multifunctional immunotherapy to treat metastatic cancer. CT101 triggers a cascade of reactions engaging multiple immune receptors and signaling pathways against cancer. CT101 effectively activates tumor-specific T cells and immune effector cells, disrupts the tumor blood supply, preventing tumor growth and metastasis, reduces the immunosuppressive tumor microenvironment to overcome cancer resistance, and prevents cancer relapse. CT101's distinction is the multifunctional mechanism of action to treat metastatic cancer.
Diamind Solutions Inc Alex Lemnaru (alex@diamindsolutions.ca) www.diamindsolutions.ca We are a Canadian team dedicated to bridging the gaps between healthcare, research, management, and technology. Our mission is to develop innovative solutions that streamline the management and execution of clinical trials, registries, and life sciences projects. Through close collaboration with academic and clinical partners, we focus on reducing costs and improving efficiencies, such as speeding up enrollment for clinical and research projects while enhancing outcomes. Our flagship product, Diamind Clinical Trials Management Solution (DCTMS), integrates advanced randomization algorithms and consolidates multiple functions—such as new Randomization algorithms, Drug Management, eConsent, Data Capture, and more—into one platform. Additionally, it offers seamless API integration with EDC systems like REDCap and DfDiscover. Having supported successful trials published in leading journals such as The Lancet, we are now poised to scale our solution and make it accessible to more researchers and life sciences organizations worldwide. Contact us at contact@diamindsolutions.ca for more information!

Presenters and Exhibitors
EvolvedBio John Cappuccitti (john@itsevolved.com) & Alireza Shahin (alireza@itsevolved.com) https://evolved.bio/ EvolvedBio is at the forefront of regenerative medicine with our unique Anchored Cell Sheet Engineering platform. This technology allows us to develop tissue replacements that closely resemble natural human tissues, promoting effective healing and integration. Our tissues are composed of only properly differentiated and mature cells and in vivo-like tissue-specific extracellular matrix produced by them. They are entirely scaffold- and biomaterial-free, resulting in proper integration and healing. Our current focus is on tackling Volumetric Muscle Loss (VML), a particularly difficult problem in tissue regeneration. Our work has already shown promising results, with our tissue constructs displaying better structure, integration, and function than traditional methods. Looking ahead, Evolved aims to apply our groundbreaking technology to a range of medical conditions, advancing toward a future where personalized and effective regenerative therapies are a reality.
Feldan Therapeutics Christine Hurley (churley@feldan.com) www.feldan.com Located in Québec City, Feldan is a biopharmaceutical company specializing in the development of treatments based on intracellular delivery of therapeutics. The company's proprietary technology, the Feldan Shuttle, is a groundbreaking peptide-based delivery platform that enables safe and efficient cytoplasmic delivery of bioactive molecules without the limitations of endosomal entrapment, a problem often faced by traditional cell-penetrating peptides. This technology is unlocking intracellular targets previously inaccessible to conventional drugs. Feldan has successfully demonstrated the Shuttle's versatility by delivering a wide array of bioactive molecules including proteins, peptides, and oligonucleotides into multiple cell types and tissues. Feldan's pipeline focuses on diseases affecting lungs and skin. This fall, Feldan will commence its first ever clinical trial; a Phase 1/2a study for FLD-103, an intralesional injection designed to provide an alternative to surgery for patients diagnosed with basal cell carcinoma. The company is also developing a drug for muco-obstructive lung diseases which is expected to enter preclinical development in 2025.
Hada Medtech Zaya McDonald (zaya@hadamedtech.com) https://hadamedtech.com/ HaDa Medtech is a medical device company to improve safety airway management. We are based in Toronto since July 2023. We have completed the fully functioning MVP. At Hada Medtech, Oxyscope™ solution is a novel platform that extends safe apnea time to prevent the patient from desaturation and to have enough time for alternative airway management procedures. This device can connect to the oxygen supply, optimizing oxygen flow automatically to reach the ideal oxygen saturation to different patients. We also noticed patients are very likely to have blood, mucus, fog in the critical care. Clinicians have to remove the scope to wipe off the lens and reinsert, or it has to be changed due to the obstructed view. This creates additional steps, increasing the apnea time and reinsertion risks. Therefore, we have developed a ClearView disposable blade, automatically clearing off the obstruction from the lens, effectively improving the visibility and the efficiency.
Heamac Inc Prasad Muddam (prasad@heamac.com) www.heamac.com Heamac's **nLite360** is the world's first robotic phototherapy device. Its innovative **multi-planar projection** and **dynamic 360-degree treatment capability** deliver **precision treatment** specifically tailored to each newborn's unique needs. This ensures **personalized therapy**, minimizing the risks of over or under-treatment. Additionally, **nLite360** supports continuous therapy, even during **breastfeeding** and **Kangaroo Mother Care**, revolutionizing neonatal care and enhancing treatment outcomes.

Presenters and Exhibitors
HOP Technologies Marc-Antoine Pelletier (mapelletier@hoptech.ca) https://hoptech.ca/ As a digital health company, HOP TECH participates in numerous clinical trials through university hospitals and pharmaceutical company collaborative agreements. Marc-Antoine Pelletier, HOP TECH's CEO will be presenting a short presentation on DISCOVERY an end-to-end digital clinical trial platform for the development of indication specific algorithms. HOP TECH business expansion with other Canadian and international partners is focused towards projects that require AI pipeline capabilities to accelerate the execution of clinical trials in respiratory diseases, type2-diabetes and heart failure.
JN Nova Pharma John Gillard (john@jnnova.com) & Nathan Yoganathan (nathan@jnnova.com) https://www.jnnova.com/ Our lead therapeutic molecules are corona-viral neutralizing agents which trap and inhibit viral entry to the lungs and have full ACE2 enzyme replacement activity, supporting protection from acute kidney injury (AKI) and enhanced recovery from the acute respiratory syndrome (ARDS) and Pulmonary Fibrosis.
Khure Health Inc. Don Watts (watts@khurehealth.ca) & Sonny Kohli (sonny.kohli@khurehealth.ca) https://khurehealth.ca/ The longer it takes to enroll patients, the more expensive trials become, and everyone loses, specifically those that can benefit from new discoveries. Deploying protocol-based AI-enabled algorithms into investigator site EMRs to screen for high fit patients will accelerate high fit patient identification, optimize CRA/study coordinator resources and speed discovery. Khure's AI Clinical Decision Support platform is available for free to thousands of Canadian and US physicians, PCPs and Specialists, who can opt in to participate in trial patient recruitment, expanding study reach, diversity and accelerate recruitment dramatically. Creating a connected, cloud-based investigator network utilizing Khure's recruitment acceleration platform also allows for pre-release protocol testing and optimization, easy cloud-based protocol changes, with instant high fit patient identification. Khure is accelerating the modernization and optimization of patient recruitment.
Living In Silico Inc. Sohail Mahmood (sohailhm91@gmail.com) www.livinginsilico.ca Living In Silico Inc. was established in 2018 with the aim to provide resource efficient solutions for therapeutics and compound discovery. Utilizing in silico simulations and fungal bioremediation we are able to accomplish these goals with a host of innovative tools. Our particular mission currently is to provide service of our fungal bioremediation system (of over 10 cell lines) for conversion of food refuse substrate utilizing unique cell lines to convert food refuse into viable industrial products. Our current project is utilizing a fungal bioremediation system for beta-glucan extraction (from valorized barley) within a unique formulation allowing us to treat mechanistic immunological processes of atopic dermatitis to outcompete emollients that only target symptoms

Presenters and Exhibitors
Loon Inc. Ghayath Janoudi (janoudi@loonbio.com) https://loonbio.com/ Loon is transforming the pharmaceutical industry by tackling challenges in clinical protocol development and market access through its AI-driven platform for evidence synthesis, HEOR, and market access forecasting. The platform enables biopharma companies to design regulatory-compliant, reimbursement-friendly, and market-ready clinical protocols, using proprietary Agentic AI to produce up-to-date evidence and Living Systematic Reviews in a matter of days. Loon goes a step further by pioneering the prediction of reimbursement decisions, conditions, and timelines. By optimizing value dossiers and simulating pricing scenarios, Loon empowers biopharma companies to position products for favorable Health Technology Assessments (HTAs). This enables biopharma to craft clinical protocols that maximize value evidence for HTA bodies and result in accelerated patient access to therapies, improved commercialization strategies, reduced revenue loss, and increased profitability.
N2 Canada Rebecca Barnes (Rebecca.barnes@n2canada.ca) https://n2canada.ca/ N2 Canada is a non-profit organization that unites Canadian research organizations to strengthen national clinical research capabilities. It brings together trialists and clinical research professionals to share best practices and resources, ensuring efficient and high-quality research while upholding the integrity of clinical practices. Over the past 17 years, N2 has created a unique environment for clinical researchers to benefit from sharing "best-in-class" tools and the expertise of others. N2 offers resources in various formats, including access to Health Canada-compliant standard operating procedures, a core education program, participant engagement tools, and best practice guidelines. N2 now hosts the CCTAM, a searchable directory of Canadian clinical trials investigators, sites, and services. In addition to promoting Canada as a premier destination for clinical trials, the CCTAM provides a tool for investigators and research teams to find others working in areas of shared research interests, creating more opportunities to collaborate. Learn more about N2.
Nimble Science Ltd Sabina Bruehlmann (Sabina@nimblesci.com) www.nimblesci.com Nimble Science is a health technology company delivering precision GI datasets leveraging the **SIMBA GI Platform**, an advanced capsule sampling technology that collects endoscopic quality intestinal liquid biopsies directly from the small intestine. Provided as a home kit, the platform enables diverse multi-omic data extraction (microbiome, metabolome, proteome etc.) synchronous with drug and/or food product ingestion. The **Nimble GI Analytics Platform** processes this data, leveraging AI and ML tools to extract spatially associated information from traditionally inaccessible GI regions. Nimble Science utilizes the platform to service researchers from both academia and industry (functional food and biopharma) to investigate novel disease and product associated intestinal reactions, and to develop novel diagnostic and therapeutic advances in GI health and beyond.
Nytia Health Nouridine Boukari (nouridine@nytialabs.com) https://nytialabs.com Nytia Health builds a Medical Technology(MedTech) platform that provides prevention interventions to NCD(Non-Communicable Diseases), killing ~41 millions people every single year globally and cost businesses in North America combined, $ 550 Billions to productivity, using our data-driven and evidence-based approach on our proprietary dataset.

Presenters and Exhibitors
Ostia Sciences Inc. Abdelahhad Barbour (contact@ostia-sciences.com) https://ostiasciences.ca/ Ostia Sciences Inc., a biotech startup based in downtown Toronto is focused on advancing healthcare by utilizing the power of beneficial microbes and their natural products to combat infectious diseases and boost immune health. Ostia has developed microbiome-based therapies including a new class of molecules called phosphorylated lantibiotics, with Salivaricin 10 being the first member of this family of antibiotics. Salivaricin 10 is a unique antimicrobial compound capable of targeting antibiotic-resistant pathogens while preserving beneficial bacteria. Currently, Ostia is designing new clinical trials including the use of Streptococcus salivarius SALI-10, a proprietary oral biotherapeutic strain that produces Salivaricin 10, to fight off oral and respiratory diseases. This innovative approach sets Ostia Sciences apart from existing market solutions. With an extensive patent portfolio covering its biotherapeutic drugs, the company leads the way in creating the next generation of treatments for disease prevention.
Ottawa Methods Centre (OMC), Ottawa Hospital Research Institute (OHRI) Julia Chehaiber (jchehaiber@ohri.ca) https://www.ohri.ca/ottawamethodscentre The Ottawa Methods Centre (OMC) at the Ottawa Hospital Research Institute has an 18-year track record of leading clinical research on a local, national, and international scale, with research sites spanning all five continents. Over the past five years, nearly 1,000 trials involving 50,800 patients, including 378 industry-sponsored trials, have been initiated at The Ottawa Hospital (TOH), with 472 completed in the same timeframe. These trials, leveraging world-class expertise in methodology, statistics, and implementation science, have significantly influenced practice across a wide range of fields, including critical care, emergency medicine, respirology, infectious diseases, renal transplantation, transfusion medicine, stroke, perioperative medicine, and perinatal health. OMC offers comprehensive services in nine key areas, including knowledge synthesis, knowledge translation, biostatistics, health economics, data management, and big data. Home to over 40 scientists and a dedicated staff team, OMC is recognized as one of Canada's leading clinical research centres.
Pentavere Aaron Leibtag (aleibtag@pentavere.com) & Christopher Pettengell (cpettengell@pentavere.com) https://pentavere.ai/ Pentavere is a Patient Identification Company that has built a best in class AI engine to identify patients that are eligible for approved medications, interventions, and clinical trials to ensure patients get the most personalized and equitable care to achieve the best health outcomes.
ProteinQure Inc. Lucas Siow (lucas@proteinqure.com) www.proteinqure.com **ProteinQure** has built the best AI platform for designing peptides for extra-cellular targets. Its lead program for TNBC will be ready for IND in Q3-2025 (and conducted in Canada + US). Our computational platform has also been validated with three top 25 pharma companies in the world. ProteinQure is the only computational approach capable of designing peptides with the full complement of non-canonical amino acids, so that its peptides are 100x better than natural peptide ligands. Our other early stage programs focus on siRNA delivery to the CNS and Kidney and we welcome engagement from clinicians who conduct trials in those areas.

Presenters and Exhibitors
RAN BioLinks Rym Ben Othman & Rad Aniba (info@ranbiolinks.com) www.ranbiolinks.com RAN BioLinks is a Canadian company driving data-driven biomedical research through advanced technology and tailored solutions. Our mission is to make research more efficient and impactful by freeing scientists from operational complexities and allowing them to focus on breakthroughs. We provide robust data platforms that empower clinical trial teams with real-time monitoring, actionable insights, and streamlined project management to enhance decision-making and optimize workflows. With leadership rooted in scientific and data expertise, RAN BioLinks delivers solutions designed by scientists for scientists. We partner with pharmaceutical companies, biotech firms, and research institutions to seamlessly integrate data from biobanking, clinical trials, and lab operations. Our tools ensure accurate data, clear project visibility, and reliable progress tracking. **Services:** Data Platforms, Data Governance, Clinical Trial Support, Real-Time Monitoring, Biobanking, Project Management, Real-Time Insights
Research Institute of the McGill University Health Center Accelerating Clinical Trials-Clinical Trials Unit (RI-MUHC ACT-CTU) Amanda Lovato (amanda.lovato@rimuhc.ca) https://rimuhc.ca/ Working together with our partners to streamline the clinical trial process across Canada is our mandate. As one out of 11 teams in the country and based in Montreal, the RI-MUHC ACT-CTU is working on improving its local resources to support the needs of its various researchers while also building its capacity to collaborate with other CTUs, portfolio hospitals and networks on clinical trials. We have a vast array of pediatric and adult clinical trialists with diverse expertise in the topics of neuroscience, oncology, cardiology, child health, infectious disease, metabolic disorders, surgical interventions and respirology for which we are building a clinical trial community for the exchange of expertise and growth of our competencies in clinical trials. We are also equipped with a large centre for innovative medicine, a resource hub fully equipped to support clinical trials from study start-up to closeout. We invite you to come visit our booth to discuss possibilities for sharing resources and collaborating!
Roga Dr. Alison Smith (alison@rogalife.com) https://www.roga.ai/ Roga is a mental healthcare platform designed to treat anxiety in the adult population. We offer a discreet wearable device (non-invasive brain stimulation) with a companion app to reduce brain activity associated with anxiety. We are currently working toward medical device clearance (class II) with Health Canada and the FDA (510k).
Sciteline Ltd. Jay Virani (jay.virani@sciteline.com) www.sciteline.com Sciteline is a focused Canadian team reshaping clinical trial software to improve access and reduce the burden of clinical trial recruitment and conduct for both participants and researchers. Since its inception in 2018, Sciteline has been working with our partners and clients to build a state-of-the art clinical trials platform that facilitates faster recruitment timelines, supports equitable access to research, and reduces researcher burden. Our modern clinical trials platform is an integrated, user-friendly toolset that combines Recruitment, Direct Data Capture and Decentralized Clinical Trial functionality into one system that streamlines clinical trial workflows, saves time and reduces staff workload. Whether you are part of a research network, a sponsor, contract research organization, research hospital or research clinic, Sciteline's platform can offer value to your clinical trials at any stage. Connect with us at our exhibitor booth, our website or directly via email at contact@sciteline.com.

Presenters and Exhibitors
Stansile Dr Pacifique Ndishimye (pndishimye@stansile.org) https://stansile.org/ Stansile, Innovating Global Health, Bridging Continents. Stansile is a pioneering clinical research organization focused on advancing clinical trials and bridging equity gaps for impactful global health solutions. Headquartered in Halifax, Canada, and with a primary hub in Huye, Rwanda, Stansile collaborates with global partners to transfer innovative technologies for diagnosing infections and repurposing local resources for therapeutic use. With its reputed clinical sites, the organization specializes in designing, managing, and executing medical research studies aimed at improving healthcare solutions in LMIC, with a focus on malaria, HIV, zika, tuberculosis, measles, cholera, and emerging zoonotic diseases like Rift Valley Fever, Ebola, and Mpox. Furthermore, equipped with fieldable and mobile sequencing technologies, Stansile empowers researchers and healthcare professionals, fostering innovation in genomic research, and ultimately reducing the burden of emerging and re-emerging infectious diseases, especially in hard to reach or conflict-affected areas. By prioritizing capacity building and ethical research, Stansile contributes to enhancing healthcare systems both in Canada and Africa.